Developer docs
API playgroundTry for free, no card

Search company profiles

Pharmicell

Full company profile

uuid0009ddl

Namestring
Pharmicell
Legal namestring
Pharmicell Co., Ltd. (주)파미셀
Websiteurl
pharmicell.com
Company typeenum
Public
Founded yearint
2002
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersYeoksamdong, South Korea
HQ citystring
Yeoksamdong
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
stem cell therapy, pharmaceutical ingredients, cell culture media, biopharmaceutical manufacturing, stem cell cosmetics
Industry4 codes
PRIMARYHLAIACAO
Specialty Injectable & Infusion Therapies (Cross-therapeutic)
SECONDARYHLAIACAG
Cardiology & Vascular Specialty Pharmaceuticals
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYEUAAAIAK
Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives
Energy, Utilities & Environment/Bioenergy, Natural Gas & Biomass/Biorefining & Bio-based Chemicals (Co-products, Bioproducts)
NAICS code4 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
  • Pharmaceutical and Medicine Manufacturing32541
SIC code3 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Industrial Organic Chemicals2860
  • Medicinal Chemicals & Botanical Products2833
Product category
Biopharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model6 records
1Stem Cell Therapy Products
TypeOne Time License
Description

Commercialized stem cell therapy products including Hearticellgram-AMI (approved 2011) and pipeline products in clinical trials. Revenue from product sales to hospitals and clinics. Additional revenue from clinical development partnerships and potential technology licensing.

pharmicell.com
2Bio-chemicals (APIs and Intermediates)
TypeOne Time License
Description

Supply of active pharmaceutical ingredients including nucleosides and mPEG to global pharmaceutical companies. Nucleosides used in gene therapy drugs and diagnostic reagents. mPEG used in pegylation drug delivery technology. Products supplied to Pfizer, Moderna, Roche, Merck, and others.

pharmicell.com
3Cosmetics (By Pharmicell Lab)
TypeOne Time License
Description

Stem cell culture media-based cosmetic products sold under By Pharmicell Lab brand. Includes skincare, hair care, and professional-use products. Distribution through professional aesthetic channels and home shopping.

pharmicell.com
4Stem Cell Banking Services
TypeSubscription Recurring
Description

Stem cell preservation and storage services for future medical use.

pharmicell.com
5CDMO Services
TypeProfessional Services
Description

Contract manufacturing and development services for cell therapy products and related research.

pharmicell.com
6Low-dielectric Electronic Materials
TypeOne Time License
Description

Specialty electronic materials for AI accelerators, 5G equipment, and semiconductor applications. Supplied to major electronics manufacturers.

pharmicell.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Supply Chain, Infrastructure, Marketing or Sales
Pricing details3 tiers
1Stem cell therapy treatment at Kim Hyun-soo Clinic
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

Approximately 20 million KRW per surgical procedure using stem cell therapy. Treatment involves extracting patient's own stem cells, 2-week culture and processing, then reinjection.

pharmicell.com
2Vita Ampoule (By Pharmicell Lab)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Renewed product with 18% pure vitamin content (increased from 13%) and 3% bone marrow stem cell conditioned media liposome (increased from 1%). Consumer retail product.

pharmicell.com
3BM SOME 200 Professional Line
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Premium professional line with 20% BM SOME concentration. Products include BM SOME 200 Ampoule and BM SOME 200 Rootive Hair Ampoule for professional MTS treatments.

pharmicell.com
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1By Pharmicell LAB (바이 파미셀 랩)
Description

Premium derma-cosmetics brand featuring human bone marrow-derived stem cell conditioned media liposome technology

pharmicell.com
+1 more record
Core offering1 text field

Pharmicell is a South Korean biopharmaceutical company operating two divisions. The Biomedical division develops and sells stem cell therapies (Hearticellgram-AMI for acute myocardial infarction, plus pipeline products Cellgram-LC, Cellgram-ED, Cellgram-CKD, Cellgram-DC), stem cell culture media (Half-Serum DMEM, PharmiSTEM hMSC Media), CDMO services, stem cell banking, and stem cell-conditioned media cosmetics under By Pharmicell Lab and Play Cell brands. The Biochemical division manufactures active pharmaceutical ingredients including nucleosides and mPEG (methoxypolyethylene glycol), low-dielectric electronic materials for AI accelerators/5G, and organophosphorus flame retardants.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • World's first stem cell therapy product approved (Hearticellgram-AMI, 2011)
+3 more records
Product overview1 text field

Pharmicell is a biopharmaceutical company operating two main business divisions: Biomedical (stem cell-based) and Biochemical (chemical-based). The Biomedical division focuses on stem cell therapy products including the world's first approved Hearticellgram®-AMI for acute myocardial infarction, and pipeline products like Cellgram-LC (liver cirrhosis), Cellgram-ED (erectile dysfunction), Cellgram-CKD (chronic kidney disease), Cellgram-DC (cancer immunotherapy), and various investigational therapies. The division also includes stem cell culture media products (Half-Serum™ DMEM, PharmiSTEM™ hMSC Media), cosmetics brands (By Pharmicell Lab, Play Cell), and stem cell banking services. The Biochemical division produces active pharmaceutical ingredients (nucleosides, mPEG), low-dielectric electronic materials for AI/semiconductor applications, and flame retardants. Recent product launches include the BM SOME 200 professional skincare/haircare line featuring proprietary bone marrow stem cell conditioned media liposome technology at 20% concentration.

Product and service19 records
1Hearticellgram-AMI
CategoryStem Cell Therapy
Description

World's first approved stem cell therapy product for acute myocardial infarction (AMI), using autologous bone marrow-derived mesenchymal stem cells administered via intracoronary injection in 10ml, 14ml, and 18ml doses. Sold to hospitals including Severance Hospital and 9 other institutions (135 patients cumulative).

2Cellgram-LC
CategoryStem Cell Therapy
Description

Stem cell therapy product for alcoholic liver cirrhosis using bone marrow-derived mesenchymal stem cells, currently in Phase 3 clinical trial at 8 institutions with 200-patient target.

3Cellgram-ED
CategoryStem Cell Therapy
Description

Stem cell therapy for erectile dysfunction administered via intracavernosal injection. Phase 2 clinical trial approved at Seoul Asan Hospital with 54-patient target.

4Cellgram-CKD
CategoryStem Cell Therapy
Description

Stem cell therapy for chronic kidney disease. Phase 1 clinical trial approved at Seoul Asan Hospital with 10-patient target.

5Cellgram-SCI
CategoryStem Cell Therapy
Description

Stem cell therapy for spinal cord injury, administered intrathecally. Published research in Neurosurgery journal demonstrating nerve regeneration effects.

6Cellgram-IS
CategoryStem Cell Therapy
Description

Stem cell therapy for cerebral infarction (ischemic stroke), administered intravenously to improve activities of daily living and reduce disability.

7Cellgram-CLI
CategoryStem Cell Therapy
Description

Stem cell therapy for critical limb ischemia, administered via intramuscular injection to patients at risk of amputation.

8Cellgram-DC
CategoryStem Cell Therapy
Description

Cancer immunotherapy vaccine using dendritic cells educated with tumor antigens, derived from bone marrow hematopoietic stem cells. Aims to induce tumor-specific immune response with minimal side effects.

9Half-Serum DMEM
CategoryCell Culture Media
Description

Proprietary cell culture medium developed by Pharmicell's R&D for stem cell research applications.

10PharmiSTEM hMSC Media
CategoryCell Culture Media
Description

Human mesenchymal stem cell (hMSC) culture medium for research and commercial applications.

11CDMO Services
CategoryCDMO Services
Description

Contract development and manufacturing organization services for cell therapy products, including quality control outsourcing and GMP facility access.

12Stem Cell Banking (Twelve)
CategoryBanking Services
Description

Stem cell storage and banking service for preserving healthy stem cells for future medical use, with 15-year storage options offered directly to consumers.

13Nucleosides and mPEG
CategoryPharmaceutical Ingredients
Description

Active pharmaceutical ingredients including nucleosides for gene therapy and diagnostic reagents, and mPEG (methoxypolyethylene glycol) for drug delivery pegylation technology. Supplied to Pfizer, Moderna, Merck, Roche, Thermo Fisher, Nektar Therapeutics, UCB, and Baxter International.

14Low-Dielectric Electronic Materials
CategoryElectronic Materials
Description

Specialty chemical products including ultra-low dielectric materials used in semiconductors and electronic components for AI accelerators, 5G network equipment, and base station antennas. Supplied to companies like Doosan Electronics (which in turn supplies Cisco).

15Flame Retardants
CategorySpecialty Chemicals
Description

Organophosphorus flame retardants for polymer materials used in mobile PCB, automotive interiors, and textiles. Supplied to global flame retardant companies including Germany's Trevira (world's No. 1 flame retardant company).

16BM SOME 200 Professional Line
CategoryStem Cell Cosmetics
Description

Premium professional derma-cosmetic line under By Pharmicell Lab featuring BM SOME liposome technology at 20% concentration, including BM SOME 200 Ampoule for skin care and BM SOME 200 Rootive Hair Ampoule for scalp and hair care used in professional MTS treatments.

17Vita Ampoule
CategoryStem Cell Cosmetics
Description

Flagship By Pharmicell Lab ampoule cosmetic product renewed with 18% pure vitamin content and 3% bone marrow stem cell conditioned media liposome (BM SOME).

18Rootive Hair Shampoo
CategoryStem Cell Cosmetics
Description

Home care hair product in the BM SOME 200 professional line, designed for scalp and hair care maintenance.

19Rootive Hair Scalp Serum
CategoryStem Cell Cosmetics
Description

Home care scalp treatment product in the BM SOME 200 professional line for scalp care and maintenance.

Scale indicator15 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-08
Description

Joint research collaboration for regenerative medicine and cell therapy. Conducted preclinical studies on allogeneic bone marrow-derived mesenchymal stem cells (BM-MSC) for severe alcoholic hepatitis treatment. Research results published in international journal Gut and Liver.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-08
Description

Co-hosted Regenerative Medicine Symposium with research presentations on stem cell therapy, exosome technology, and AI applications in cell therapy. Ongoing joint research programs and clinical trials.

Strategic tierCoreTypeTechnology or Integration
Description

Exclusive supplier of flame retardant materials to Trevira, the world's No. 1 flame retardant company. Partnership established after 4 years of persuasion efforts, successfully displacing US competitors.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Korean biopharmaceutical company developing biosimilars and novel biologics. Direct peer to Pharmicell as a publicly-traded Korean biotech with operations in specialty pharmaceutical manufacturing and growing international presence.

TypeBroad incumbent
Description

Korea's largest biopharmaceutical CDMO with end-to-end contract development and manufacturing capabilities. Direct peer to Pharmicell's CDMO services division and broader biologics manufacturing footprint.

TypeDirect peer
Description

Australia-listed cell therapy company developing allogeneic mesenchymal stem cell therapies including revascor for cardiovascular indications (chronic heart failure). Direct stem cell therapy peer competing with Pharmicell's Hearticellgram-AMI franchise.

4Athersys
TypeDirect peer
Description

US-based clinical-stage cell therapy company developing MultiStem, an allogeneic stem cell platform for inflammatory, immune-mediated, cardiovascular and neurological conditions. Direct stem cell therapy competitor to Pharmicell's Cellgram pipeline.

5Amorepacific
TypeRegional player
Description

Korea's largest cosmetics company with biotech-derived skincare lines. Peer to Pharmicell's By Pharmicell Lab cosmetics business in the premium derma-cosmetics channel using proprietary stem cell conditioned media technology.

TypeBroad incumbent
Description

Global CRO/CDMO providing cell therapy development services, API manufacturing, and biologics testing. Direct peer to Pharmicell's CDMO services and competing nucleoside/API supply capability.

TypeBroad incumbent
Description

Global leader in cell and gene therapy CDMO services offering GMP manufacturing for autologous and allogeneic cell therapies. Direct peer to Pharmicell's CDMO services for cell therapy products and related contract manufacturing.

8Pluristem Therapeutics
TypeDirect peer
Description

Israel-based company developing placenta-derived allogeneic cell therapies. Direct peer in regenerative cell therapy space; relevant as a competitor evaluating allogeneic scalability vs Pharmicell's autologous workflow.

TypeRegional player
Description

Major Korean pharmaceutical company developing branded innovative drugs across cardiometabolic, oncology, and immunology. Direct peer as a Korean pharma with branded specialty pharmaceutical pipeline exposure.

TypeRegional player
Description

Korean vaccine and biotech company with cell culture-based biomanufacturing capabilities. Peer to Pharmicell's biologics manufacturing infrastructure and vaccine-relevant stem cell applications.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers9 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Pharmicell

Biopharmaceuticalspharmicell.com

Pharmicell firmographics

Firmographics
Name
Pharmicell
Legal name
Pharmicell Co., Ltd. (주)파미셀
Website
https://pharmicell.com
Company type
Public
Founded year
2002
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Pharmicell industry classification

Industry
Product category
Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Pharmaceutical and Medicine Manufacturing (32541)
SIC
Biological Products, (No Disgnostic Substances) (2836), Industrial Organic Chemicals (2860), Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAIACAO
Specialty Injectable & Infusion Therapies (Cross-therapeutic)
SECONDARYHLAIACAG
Cardiology & Vascular Specialty Pharmaceuticals
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYEUAAAIAK
Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives
Energy, Utilities & Environment/Bioenergy, Natural Gas & Biomass/Biorefining & Bio-based Chemicals (Co-products, Bioproducts)

Keywords

  • Stem cell therapy
  • Pharmaceutical ingredients
  • Cell culture media
  • Biopharmaceutical manufacturing
  • Stem cell cosmetics

Where Pharmicell is headquartered

Location

Headquarters

HQ city
Yeoksamdong
HQ country
South Korea
HQ region
Asia

Offices3 records

Markets served

Pharmicell business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

  1. Stem Cell Therapy Products: Commercialized stem cell therapy products including Hearticellgram-AMI (approved 2011) and pipeline products in clinical trials. Revenue from product sales to hospitals and clinics. Additional revenue from clinical development partnerships and potential technology licensing.
  2. Bio-chemicals (APIs and Intermediates): Supply of active pharmaceutical ingredients including nucleosides and mPEG to global pharmaceutical companies. Nucleosides used in gene therapy drugs and diagnostic reagents. mPEG used in pegylation drug delivery technology. Products supplied to Pfizer, Moderna, Roche, Merck, and others.
  3. Cosmetics (By Pharmicell Lab): Stem cell culture media-based cosmetic products sold under By Pharmicell Lab brand. Includes skincare, hair care, and professional-use products. Distribution through professional aesthetic channels and home shopping.
  4. Stem Cell Banking Services: Stem cell preservation and storage services for future medical use.
  5. CDMO Services: Contract manufacturing and development services for cell therapy products and related research.
  6. Low-dielectric Electronic Materials: Specialty electronic materials for AI accelerators, 5G equipment, and semiconductor applications. Supplied to major electronics manufacturers.

Pricing tiers

ModelBillingPrice
One time/ perpetual licensePay-as-you-goStem cell therapy treatment at Kim Hyun-soo Clinic
Unit PricingPay-as-you-goVita Ampoule (By Pharmicell Lab)
Unit PricingPay-as-you-goBM SOME 200 Professional Line

Go-to-market motion1 record

Distribution channels6 records

Marketing channels6 records

Pharmicell product offering

Product offering

Core offering

Pharmicell is a South Korean biopharmaceutical company operating two divisions. The Biomedical division develops and sells stem cell therapies (Hearticellgram-AMI for acute myocardial infarction, plus pipeline products Cellgram-LC, Cellgram-ED, Cellgram-CKD, Cellgram-DC), stem cell culture media (Half-Serum DMEM, PharmiSTEM hMSC Media), CDMO services, stem cell banking, and stem cell-conditioned media cosmetics under By Pharmicell Lab and Play Cell brands. The Biochemical division manufactures active pharmaceutical ingredients including nucleosides and mPEG (methoxypolyethylene glycol), low-dielectric electronic materials for AI accelerators/5G, and organophosphorus flame retardants.

Product overview

Pharmicell is a biopharmaceutical company operating two main business divisions: Biomedical (stem cell-based) and Biochemical (chemical-based). The Biomedical division focuses on stem cell therapy products including the world's first approved Hearticellgram®-AMI for acute myocardial infarction, and pipeline products like Cellgram-LC (liver cirrhosis), Cellgram-ED (erectile dysfunction), Cellgram-CKD (chronic kidney disease), Cellgram-DC (cancer immunotherapy), and various investigational therapies. The division also includes stem cell culture media products (Half-Serum™ DMEM, PharmiSTEM™ hMSC Media), cosmetics brands (By Pharmicell Lab, Play Cell), and stem cell banking services. The Biochemical division produces active pharmaceutical ingredients (nucleosides, mPEG), low-dielectric electronic materials for AI/semiconductor applications, and flame retardants. Recent product launches include the BM SOME 200 professional skincare/haircare line featuring proprietary bone marrow stem cell conditioned media liposome technology at 20% concentration.

Differentiator

Problem solved

Functional benefit

Brands

  • By Pharmicell LAB (바이 파미셀 랩): Premium derma-cosmetics brand featuring human bone marrow-derived stem cell conditioned media liposome technology
  • Play Cell (플레이 셀)

Products and services

  • Hearticellgram-AMI World's first approved stem cell therapy product for acute myocardial infarction (AMI), using autologous bone marrow-derived mesenchymal stem cells administered via intracoronary injection in 10ml, 14ml, and 18ml doses. Sold to hospitals including Severance Hospital and 9 other institutions (135 patients cumulative).
  • Cellgram-LC Stem cell therapy product for alcoholic liver cirrhosis using bone marrow-derived mesenchymal stem cells, currently in Phase 3 clinical trial at 8 institutions with 200-patient target.
  • Cellgram-ED Stem cell therapy for erectile dysfunction administered via intracavernosal injection. Phase 2 clinical trial approved at Seoul Asan Hospital with 54-patient target.
  • Cellgram-CKD Stem cell therapy for chronic kidney disease. Phase 1 clinical trial approved at Seoul Asan Hospital with 10-patient target.
  • Cellgram-SCI Stem cell therapy for spinal cord injury, administered intrathecally. Published research in Neurosurgery journal demonstrating nerve regeneration effects.
  • Cellgram-IS Stem cell therapy for cerebral infarction (ischemic stroke), administered intravenously to improve activities of daily living and reduce disability.
  • Cellgram-CLI Stem cell therapy for critical limb ischemia, administered via intramuscular injection to patients at risk of amputation.
  • Cellgram-DC Cancer immunotherapy vaccine using dendritic cells educated with tumor antigens, derived from bone marrow hematopoietic stem cells. Aims to induce tumor-specific immune response with minimal side effects.
  • Half-Serum DMEM Proprietary cell culture medium developed by Pharmicell's R&D for stem cell research applications.
  • PharmiSTEM hMSC Media Human mesenchymal stem cell (hMSC) culture medium for research and commercial applications.
  • CDMO Services Contract development and manufacturing organization services for cell therapy products, including quality control outsourcing and GMP facility access.
  • Stem Cell Banking (Twelve) Stem cell storage and banking service for preserving healthy stem cells for future medical use, with 15-year storage options offered directly to consumers.
  • Nucleosides and mPEG Active pharmaceutical ingredients including nucleosides for gene therapy and diagnostic reagents, and mPEG (methoxypolyethylene glycol) for drug delivery pegylation technology. Supplied to Pfizer, Moderna, Merck, Roche, Thermo Fisher, Nektar Therapeutics, UCB, and Baxter International.
  • Low-Dielectric Electronic Materials Specialty chemical products including ultra-low dielectric materials used in semiconductors and electronic components for AI accelerators, 5G network equipment, and base station antennas. Supplied to companies like Doosan Electronics (which in turn supplies Cisco).
  • Flame Retardants Organophosphorus flame retardants for polymer materials used in mobile PCB, automotive interiors, and textiles. Supplied to global flame retardant companies including Germany's Trevira (world's No. 1 flame retardant company).
  • BM SOME 200 Professional Line Premium professional derma-cosmetic line under By Pharmicell Lab featuring BM SOME liposome technology at 20% concentration, including BM SOME 200 Ampoule for skin care and BM SOME 200 Rootive Hair Ampoule for scalp and hair care used in professional MTS treatments.
  • Vita Ampoule Flagship By Pharmicell Lab ampoule cosmetic product renewed with 18% pure vitamin content and 3% bone marrow stem cell conditioned media liposome (BM SOME).
  • Rootive Hair Shampoo Home care hair product in the BM SOME 200 professional line, designed for scalp and hair care maintenance.
  • Rootive Hair Scalp Serum Home care scalp treatment product in the BM SOME 200 professional line for scalp care and maintenance.

Quantifiable outcome

  • World's first stem cell therapy product approved (Hearticellgram-AMI, 2011)
  • +3 more outcomes

Companies that use Pharmicell

Customer profile

Named customers9 records

Segments5 records

Ideal customer profiles5 records

Pharmicell technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Pharmicell partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Yonsei University Wonju College of Medicine (연세대학교 원주의과대학)coreStrategic or Co-development Partner · 8 May 2026Joint research collaboration for regenerative medicine and cell therapy. Conducted preclinical studies on allogeneic bone marrow-derived mesenchymal stem cells (BM-MSC) for severe alcoholic hepatitis treatment. Research results published in international journal Gut and Liver.
  • Wonju Severance Christian Hospital (원주연세의료원)coreStrategic or Co-development Partner · 8 May 2026Co-hosted Regenerative Medicine Symposium with research presentations on stem cell therapy, exosome technology, and AI applications in cell therapy. Ongoing joint research programs and clinical trials.
  • Trevira GmbH (Germany)coreTechnology or IntegrationExclusive supplier of flame retardant materials to Trevira, the world's No. 1 flame retardant company. Partnership established after 4 years of persuasion efforts, successfully displacing US competitors.

Scale indicators15 records

Recent moves9 records

Expansion highlights5 records

Pharmicell competitors and assessment

Company assessment

Direct peers

  • Celltrion: Korean biopharmaceutical company developing biosimilars and novel biologics. Direct peer to Pharmicell as a publicly-traded Korean biotech with operations in specialty pharmaceutical manufacturing and growing international presence.
  • Mesoblast: Australia-listed cell therapy company developing allogeneic mesenchymal stem cell therapies including revascor for cardiovascular indications (chronic heart failure). Direct stem cell therapy peer competing with Pharmicell's Hearticellgram-AMI franchise.
  • Athersys: US-based clinical-stage cell therapy company developing MultiStem, an allogeneic stem cell platform for inflammatory, immune-mediated, cardiovascular and neurological conditions. Direct stem cell therapy competitor to Pharmicell's Cellgram pipeline.
  • Pluristem Therapeutics: Israel-based company developing placenta-derived allogeneic cell therapies. Direct peer in regenerative cell therapy space; relevant as a competitor evaluating allogeneic scalability vs Pharmicell's autologous workflow.

Broad incumbents

  • Samsung Biologics: Korea's largest biopharmaceutical CDMO with end-to-end contract development and manufacturing capabilities. Direct peer to Pharmicell's CDMO services division and broader biologics manufacturing footprint.
  • WuXi AppTec: Global CRO/CDMO providing cell therapy development services, API manufacturing, and biologics testing. Direct peer to Pharmicell's CDMO services and competing nucleoside/API supply capability.
  • Lonza Group: Global leader in cell and gene therapy CDMO services offering GMP manufacturing for autologous and allogeneic cell therapies. Direct peer to Pharmicell's CDMO services for cell therapy products and related contract manufacturing.

Regional players

  • Amorepacific: Korea's largest cosmetics company with biotech-derived skincare lines. Peer to Pharmicell's By Pharmicell Lab cosmetics business in the premium derma-cosmetics channel using proprietary stem cell conditioned media technology.
  • Hanmi Pharmaceutical: Major Korean pharmaceutical company developing branded innovative drugs across cardiometabolic, oncology, and immunology. Direct peer as a Korean pharma with branded specialty pharmaceutical pipeline exposure.
  • SK Bioscience: Korean vaccine and biotech company with cell culture-based biomanufacturing capabilities. Peer to Pharmicell's biologics manufacturing infrastructure and vaccine-relevant stem cell applications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

Pharmicell social profiles

Digital presence

Pharmicell financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Pharmicell leadership team

Management profile

Number of profiles

Profiles4 records

Pharmicell subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Pharmicell funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Pharmicell M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pharmicell

What does Pharmicell do?

Pharmicell is a South Korean biopharmaceutical company operating two divisions. The Biomedical division develops and sells stem cell therapies (Hearticellgram-AMI for acute myocardial infarction, plus pipeline products Cellgram-LC, Cellgram-ED, Cellgram-CKD, Cellgram-DC), stem cell culture media (Half-Serum DMEM, PharmiSTEM hMSC Media), CDMO services, stem cell banking, and stem cell-conditioned media cosmetics under By Pharmicell Lab and Play Cell brands. The Biochemical division manufactures active pharmaceutical ingredients including nucleosides and mPEG (methoxypolyethylene glycol), low-dielectric electronic materials for AI accelerators/5G, and organophosphorus flame retardants.

Is Pharmicell a public or private company?

Pharmicell is a public company. It is classified as public and is currently operating.

When was Pharmicell founded?

Pharmicell was founded in 2002. It employs 11 to 50 people.

Where is Pharmicell based?

Pharmicell is headquartered in Yeoksamdong, South Korea, in the Asia region.

How does Pharmicell make money?

Six revenue lines are on record. Stem Cell Therapy Products are the primary driver. The others are bio-chemicals (APIs and Intermediates), cosmetics (By Pharmicell Lab), stem Cell Banking Services, CDMO Services and low-dielectric Electronic Materials.

Who are Pharmicell's main competitors?

Direct peers on record are Celltrion, Mesoblast, Athersys and Pluristem Therapeutics. Broad incumbents are Samsung Biologics, WuXi AppTec and Lonza Group. Regional players are Amorepacific, Hanmi Pharmaceutical and SK Bioscience.

Does Pharmicell have an API?

No public API is recorded for Pharmicell.

What industry is Pharmicell in?

Pharmicell's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAIACAO, Specialty Injectable & Infusion Therapies (Cross-therapeutic), with a secondary code of HLAIACAG, Cardiology & Vascular Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The WorldfolioThe Worldfolio: Pharmicell's bold vision for healthcare transformationPharmicell is advancing its pipeline with a new phase one clinical trial for autologous dendritic cell therapy targeting pancreatic cancer in Korea. The company continues to expand its global supply of nucleosides to major pharmaceutical partners including Thermo Fisher, UCB, and ST Pharm while developing novel stem cell treatments for liver disease and erectile dysfunction.PR NewswireGlobal Stem Cell Therapy Market Report 2020-2030 Featuring Major Players | Anterogen, JCR, Medipost, Osiris Therapeutics, Pharmicell, Astellas, Cellectis, Celyad, Novadip Biosciences and Gamida CellResearch and Markets has added the "Stem Cell Therapy Global Market Report 2020-30" to its offerings, detailing market trends and key players such as Anterogen, JCR Pharmaceuticals, and Astellas Pharma. The report indicates the global stem cell therapy market declined from $8.73 billion in 2019 to $8.62 billion in 2020 due to COVID-19 but is projected to recover to $14.76 billion by 2023 at a CAGR of 19.62%. Key drivers include rising chronic disease prevalence, while restraints involve high treatment costs and economic pressures.PR NewswireStem Cell Therapy Market by Type, Therapeutic Application, Cell Source - Global Forecasts to 2021A market research report forecasts the global stem cell therapy market to reach USD 145.8 million by 2021, growing at a CAGR of 11.0% from 2016. The North American region is expected to hold the largest market share, while Japan, South Korea, and China offer new growth opportunities. Key players identified in the competitive landscape include Osiris Therapeutics, MEDIPOST Co., Ltd., Anterogen Co., Ltd., and Pharmicell Co., Ltd.PR NewswireStem Cell Therapies Market - 330 Pipeline Products, yet Commercial Challenges PrevailRnRMarketResearch.com released a 2016 market research report analyzing the global stem cell therapy sector, highlighting that while there are 330 products in the pipeline, commercial viability remains limited by significant scientific and regulatory hurdles. The report identifies key industry players such as Mesoblast, Pharmicell, and Cynata Therapeutics, noting that manufacturers must adopt novel strategies like automated systems to overcome current obstacles.